High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Zhan
Fenghuang
F
Barlogie
Bart
B
Mulligan
George
G
Shaughnessy
John D
JD
Bryant
Barb
B
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D017326:Clinical Trials, Phase III as Topic; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008954:Models, Biological; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D011237:Predictive Value of Tests; D011719:Pyrazines / Q000008:administration & dosage*; D012307:Risk Factors; D013997:Time Factors
D000970:Antineoplastic Agents; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone